// App-Quantinova.ai

AB0461 (2018) : Experience with subcutaneous abatacept in routine clinical practice: 6-month interim analysis of a 2-year, prospective, non-interventional, multicentre study in patients with ra

Researchers

Presenter

  • R. Alten

Principal Investigators

  • X. Mariette

  • M. Buch

  • R. Caporali

  • R.-M. Flipo

  • A. Forster

  • H. Griffiths

  • M. Nurmohamed

  • Y. Patel

  • P. Peichl

  • R. Sanmarti

  • C. Chauvet

  • J. Heitzman

  • C. Rauch

  • S.E. Connolly

Medical Centers

  • Charite-University Medicine Berlin, Berlin, Germany

  • University Paris-Sud, Paris, France

  • University of Leeds, Leeds, UK

  • University of Pavia, Pavia, Italy

  • Centre Hospitalier Universitaire de Brest, Brest, France

  • Schulthess Clinic, Zurich, Switzerland

  • Haematology,University Hospital Geelong,Geelong,Australia

  • VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands

  • Hull Royal Infirmary, Hull, UK

  • Evangelical Hospital, Vienna, Austria

  • Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

  • DOCS, Nanterre

  • Excelya, Boulogne-Billancourt, France,

  • Bristol-Myers Squibb, Munich, Germany

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • Germany

  • France

  • United Kingdom

  • Italy

  • Switzerland

  • Australia

  • Netherlands

  • Austria

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

  • Estrogen receptor alpha

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT02090556

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved